Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab or nivolumab + ipilimumab versus ipilimumab in unresectable or metastatic melanoma (Phase 3)
2012-005371-13Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Started Apr 2013; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-005371-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005371-13.